Digital Resources - CYSTADROPS (cysteamine ophthalmic solution) 0.37%

For US Audiences Only

FOR U.S. HEALTHCARE PROFESSIONALS

FOR U.S. PATIENTS

Contact a Recordati Rare Diseases Representative

Download Patient Treatment Form

Download CYSTADROPS Trial Voucher

For US Audiences Only

CYSTADROPS Treatment Form

To initiate treatment with CYSTADROPS, submit the form by fax to Anovo Specialty Pharmacy (855)-813-2039.

DOWNLOAD EMAIL

Starting your patients on CYSTADROPS

Helpful tips for healthcare providers initiating treatment with CYSTADROPS.

DOWNLOAD EMAIL

For your CYSTADROPS patients: Patient Liaison (PL) Program Opt-In Form

To enroll, your patients or their caregivers can complete the opt-in form available via the link below.

OPT-IN EMAIL

CYSTADROPS Dosing, Storage & Administration Guide

Helpful information for your new to treatment patients on dosing, storage, and step-by-step administration process.

DOWNLOAD EMAIL

Dr. Syed’s CYSTADROPS Presentation

Hear Dr. Syed share insights on treating corneal cystine crystals in cystinosis with CYSTADROPS.

Contact Recordati Rare Diseases Representative for additional information and ongoing support

X

Indications and Usage

CYSTADROPS^® (cysteamine ophthalmic solution) 0.37% is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis.

Important Safety Information

Contamination of Tip and Solution: To minimize the risk of contamination, do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use.
Benign Intracranial Hypertension: Benign intracranial hypertension (or pseudotumor cerebri) associated with oral cysteamine or ophthalmic use of cysteamine (with concurrent oral cysteamine) has been reported, which has resolved with diuretic therapy.
Contact Lens Use: Contains benzalkonium chloride. Contact with soft contact lenses should be avoided. Remove contact lenses prior to application. Lenses may be reinserted 15 minutes following administration.
The most common adverse reactions (≥ 10%) are eye pain, vision blurred, eye irritation, ocular hyperaemia, instillation site discomfort, eye pruritus, lacrimation increased, and ocular deposits.
To report SUSPECTED ADVERSE REACTIONS, contact Recordati Rare Diseases Inc. at 1-888-575-8344, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

CYSTADROPS^® (cysteamine ophthalmic solution), for topical ophthalmic use, is available as 3.8 mg/mL of cysteamine (0.37%) in 5 mL bottles.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

+ SEE MORE

Important Safety Information

Contamination of Tip and Solution: To minimize the risk of contamination, do not touch the dropper tip to any surface. Keep bottle tightly closed when not in use.